DHR - NYSE

Danaher Corporation

DHR·NYSE

$178.08

-1.0%

HealthcareMedical - Diagnostics & Research

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$126.04B

EPS5.0700

P/E Ratio44.80

Earnings Date07/28/2026

83.46B

Assets

3Y-1.0%

5Y+10.0%

10Y+84.0%

30.93B

Total Liabilities

10%

3Y-10.0%

5Y-15.0%

10Y+39.0%

52.54B

Total Equity

3Y+5.0%

5Y+32.0%

10Y+128.0%

Danaher Corporation Funding & Solvency Profile

DHR · NYSE

Current Assets

Cash & Cash Equivalents4.62B

Net Receivables3.91B

Inventory2.49B

Other Current Assets1.74B

Total Current Assets13 B

Non-Current Assets

Property, Plant & Equipment5.53B

Goodwill & Intangible Assets60.97B

Long-Term Investments0.00

Other Non-Current Assets4.21B

Total Non-Current Assets10 B

Total Assets

83.46B

Financial Health Analysis

Current Ratio

1.87x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

0.59x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

6 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

15% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Danaher Corporation Balance Sheet

DHR • NYSE

Danaher Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	4.6B	2.1B	5.9B	6B	2.6B	6B	19.9B	787.8M	630.3M	963.7M	790.8M	3B	3.1B	1.7B	537M	1.6B	1.7B	392.9M	239.1M	317.8M
Cash & Short-Term Investments	4.6B	2.1B	5.9B	6B	2.6B	6B	19.9B	787.8M	630.3M	963.7M	790.8M	3B	3.1B	1.7B	537M	1.6B	1.7B	392.9M	239.1M	317.8M
Net Receivables	3.9B	4.4B	4.6B	5.1B	5.4B	4.8B	3.3B	3.1B	3.5B	3.2B	3B	3.6B	3.5B	3.3B	3B	2.2B	1.9B	1.9B	2B	1.7B
Accounts Receivables	3.9B	3.5B	3.9B	4.1B	4.6B	4.1B	3.3B	3.1B	3.5B	3.2B	3B	3.6B	3.5B	3.3B	3B	2.2B	1.9B	1.9B	2B	1.7B
Other Receivables	0.0	853M	715M	962M	812M	700M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	2.5B	2.3B	2.6B	2.8B	2.8B	2.3B	1.6B	1.6B	1.8B	1.7B	1.6B	1.8B	1.8B	1.8B	1.8B	1.2B	993M	1.1B	1.2B	1B
Prepaids	0.0	620M	771M	700M	770M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	757.4M	0.0	0.0
Other Current Assets	1.7B	79M	71M	1.4B	82M	665M	787.6M	1.6B	857.1M	805.9M	2.5B	960.4M	763.4M	828.4M	904.1M	652.4M	588.9M	0.0	632.7M	396.8M
Total Current Assets	12.8B	9.5B	13.9B	15.9B	11.6B	13.8B	25.6B	7.1B	6.9B	6.7B	7.8B	9.4B	9.1B	7.6B	6.3B	5.7B	5.2B	4.2B	4B	3.4B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	5.5B	6.1B	5.6B	4.6B	4.8B	4.2B	3.1B	2.2B	2.5B	2.4B	2.3B	2.2B	2.2B	2.1B	2.1B	1.2B	1.1B	1.1B	1.1B	874.4M
Goodwill	43.2B	40.5B	41.6B	37.3B	41.2B	35.4B	22.7B	22.6B	25.1B	23.8B	21B	17B	16B	15.5B	14.5B	10.8B	9.8B	9.2B	9.2B	6.6B
Intangible Assets	17.8B	18.6B	20.7B	19.8B	22.8B	21.3B	9.7B	10.3B	11.7B	11.8B	10.5B	7.4B	6.2B	6.3B	5.8B	3.3B	2.7B	2.5B	2.6B	1.7B
Goodwill & Intangible Assets	61B	59.1B	62.4B	57.1B	64B	56.7B	32.5B	32.9B	36.8B	35.6B	31.6B	24.3B	22.3B	21.8B	20.3B	14.1B	12.5B	11.7B	11.8B	8.3B
Long-Term Investments	0.0	1.8B	1.7B	2.2B	1.3B	27M	33.7M	38.3M	45.4M	170.1M	401.4M	257.5M	385.2M	877.8M	808.9M	768.3M	219.1M	0.0	0.0	0.0
Other Non-Current Assets	4.2B	1.1B	896M	4.6B	1.4B	1.4B	923.4M	5.6B	492.9M	461.2M	6.1B	766.5M	676.1M	528.5M	452.7M	444.1M	538.9M	464.4M	507.6M	300.4M
Total Non-Current Assets	70.7B	68B	70.6B	68.5B	71.5B	62.4B	36.5B	40.7B	39.8B	38.6B	40.4B	27.6B	25.6B	25.4B	23.7B	16.5B	14.4B	13.3B	13.4B	9.5B
Total Assets	83.5B	77.5B	84.5B	84.4B	83.2B	76.2B	62.1B	47.8B	46.6B	45.3B	48.2B	37B	34.7B	32.9B	29.9B	22.2B	19.6B	17.5B	17.5B	12.9B
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.8B	2.3B	2.3B	2.5B	3.3B	2.6B	1.9B	1.8B	1.9B	1.8B	1.8B	2.4B	2B	1.7B	1.7B	1.4B	1.2B	1.1B	1.4B	1.4B
Accounts Payable	1.8B	1.8B	1.8B	1.9B	2.6B	2B	1.5B	1.5B	1.5B	1.5B	1.4B	1.9B	1.8B	1.5B	1.4B	1.2B	1.1B	1.1B	1.1B	952.3M
Other Payables	0.0	568M	582M	621M	707M	552M	356.5M	286M	386.4M	293.9M	381.2M	566.9M	224.9M	194.5M	234M	206.5M	161.9M	0.0	237.5M	437.6M
Accrued Expenses	0.0	1.2B	1.2B	1.2B	1.4B	1.5B	1.1B	973M	1.1B	1B	877.2M	1B	891.9M	835.9M	845.5M	708.2M	559.2M	1.6B	544M	476M
Short Term Debt	2M	505M	1.9B	758M	215M	200M	370.2M	51.8M	194.7M	2.6B	845.2M	71.9M	62.3M	55.5M	98.4M	40.8M	44.2M	66.2M	330.5M	10.9M
Capital Lease Obligations (Current)	0.0	173M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	582M	691M	707M	552M	356.5M	292.4M	386.4M	293.9M	422.3M	566.9M	224.9M	194.5M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	1.3B	1.5B	1.5B	1.6B	1.2B	687.8M	626.8M	666M	539.8M	457M	766.5M	686.5M	730M	645M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	5B	1.3B	1.4B	2.5B	1.6B	1.9B	921.1M	1.4B	978.5M	954.7M	2.2B	1.1B	883.6M	843.9M	926.7M	1.1B	944.1M	0.0	662.3M	582.7M
Total Current Liabilities	6.8B	6.8B	8.3B	8.4B	8.1B	7.4B	4.9B	4.8B	4.8B	6.9B	6.2B	5.4B	4.6B	4.2B	4.2B	3.3B	2.8B	2.7B	2.9B	2.5B
NON-CURRENT LIABILITIES
Long Term Debt	18.4B	15.5B	16.7B	19.1B	22.2B	21.2B	21.5B	9.7B	10.3B	9.7B	12B	3.4B	3.4B	5.3B	5.2B	2.8B	2.9B	2.6B	3.4B	2.4B
Deferred Revenue (Non-Current)	0.0	232M	249M	221M	213M	205M	118.1M	109.8M	104.9M	92.7M	76.5M	186.8M	170.2M	105.2M	75.7M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	5.7B	4.5B	4.8B	5.8B	6.6B	6.8B	4.6B	5B	5.1B	5.6B	6.2B	4.6B	4.1B	4.3B	3.5B	2.4B	2.3B	2.4B	2.1B	1.3B
Total Non-Current Liabilities	24.1B	21.2B	22.7B	25.9B	29.9B	29B	26.9B	14.8B	15.5B	15.3B	18.3B	8.1B	7.7B	9.7B	8.8B	5.1B	5.2B	4.9B	5.5B	3.8B
Capital Lease Obligations	0.0	1.1B	954M	772M	889M	785M	796.9M	0.0	0.0	15.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	30.9B	28B	31B	34.3B	38B	36.4B	31.8B	19.6B	20.3B	22.2B	24.5B	13.5B	12.2B	13.9B	13B	8.4B	8B	7.7B	8.4B	6.2B
SHAREHOLDERS' EQUITY
Treasury Stock	-11.4B	-8.2B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	1.7B	3.3B	3.3B	1.6B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	9M	9M	9M	9M	9M	9M	8.4M	8.2M	8.1M	8.1M	8M	7.9M	7.9M	7.7M	7.6M	7.3M	3.6M	3.5M	3.5M	3.4M
Additional Paid-In Capital	17.2B	16.7B	14.2B	12.1B	10.1B	9.7B	7.6B	5.8B	5.5B	5.3B	5B	4.5B	4.2B	3.7B	3.9B	2.4B	2.1B	1.8B	1.7B	1B
Retained Earnings	46.9B	44.2B	41.1B	39.2B	32.8B	27.2B	24.2B	25.2B	22.8B	20.7B	21B	20.3B	18B	15.4B	13.1B	10.9B	9.2B	8.1B	6.8B	5.4B
Accumulated Other Comprehensive Income/Loss	-207M	-3.2B	-1.7B	-2.9B	-1B	-368M	-3.1B	-2.8B	-2B	-3B	-2.3B	-1.4B	214.5M	-59.2M	-36.9M	345.4M	346.9M	-103.1M	542.7M	192M
Total Stockholders' Equity	52.5B	49.5B	53.5B	50.1B	45.2B	39.8B	30.3B	28.2B	26.4B	23B	23.7B	23.4B	22.4B	19B	16.9B	13.7B	11.6B	9.8B	9.1B	6.6B
Total Equity	52.5B	49.6B	53.5B	50.1B	45.2B	39.8B	30.3B	28.2B	26.4B	23.1B	23.8B	23.4B	22.5B	19.1B	17B	13.8B	11.6B	9.8B	9.1B	6.6B
Minority Interest	7M	7M	4M	8M	10M	11M	11.3M	12.3M	9.6M	74M	73.7M	71.7M	66.1M	67.4M	67M	61.8M	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	83.5B	77.5B	84.5B	84.4B	83.2B	76.2B	62.1B	47.8B	46.6B	45.3B	48.2B	37B	34.7B	32.9B	29.9B	22.2B	19.6B	17.5B	17.5B	12.9B
Total Investments	0.0	1.8B	1.7B	2.2B	1.3B	27M	33.7M	38.3M	45.4M	170.1M	401.4M	257.5M	385.2M	877.8M	808.9M	768.3M	219.1M	0.0	0.0	0.0
Total Debt	18.4B	17.1B	19.5B	20.6B	23.3B	22.2B	22.5B	9.7B	10.5B	12.3B	12.9B	3.5B	3.5B	5.3B	5.3B	2.8B	2.9B	2.6B	3.7B	2.4B
Net Debt	13.8B	15.1B	13.7B	14.6B	20.7B	16.1B	2.6B	9B	9.9B	11.3B	12.1B	467.8M	383.8M	3.7B	4.8B	1.2B	1.2B	2.2B	3.5B	2.1B
Shares Outstanding	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413	716,525,413

SEC Filings

DHR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 21, 2026	April 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 21, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 17, 2026	April 16, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 25, 2026	May 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 10, 2026	February 05, 2026	2026	View Filing

Showing 1 to 10 of 477 filings

Related Guides

Blog Categories

Continue your DHR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.